Literature DB >> 1578954

Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).

R Ohno1, T Kobayashi, Y Morishima, A Hiraoka, K Imai, N Asoh, K Tsubaki, M Tomonaga, I Takahashi, K Kodera.   

Abstract

We asked 2 questions in this study. First was the additional effect of VCR in induction therapy, and the second was the duration of maintenance therapy. Adult AML were treated by an individualized response-oriented induction therapy with behenoyl Ara-C 200 mg/m2 daily + 6MP 70 mg/m2 daily + prednisolone 40 mg/m2 on days 1-4 + DNA 40 mg/m2 on days 1-3 and additionally on days 7, 8, 11, 12 (for M3, DNR 50 mg/m2 daily) (BHAC-DMP) until bone marrow became severely hypoplastic with less than 5% of blasts. Patients were randomized to BHAC-DMP or BHAC-DMP + VCR 0.35 mg/m2 on days 1-4. After obtaining CR, 3 courses of intensive consolidation therapy were given together with I.T. MTX+Ara-C+PSL. Maintenance intensification therapy was randomized to either 4 or 12 courses given every 2 months. Patients of age greater than or equal to 60 received about 2/3 reduced doses. From June 1987 to Sept. 1989, 265 consecutive adult AML were registered from 19 institutions and 258 were evaluable. Age ranged from 15 to 79 (med., 48). Out of 258, 200 (77.5%) achieved CR (80% in 209 of age less than 60 and 65% in 49 of age greater than or equal to 60). Unexpectedly, addition of VCR reduced the high CR rate of BHAC-DMP significantly (84% to 70%, p = 0.007). At the median follow-up of 37 mo., overall survival is 37%, and event-free survival (EVS) 27%. Survival, continuing CR and disease-free survival (DFS) rates of 200 CR cases are 45%, 40% and 35%, respectively. Patients received 12 courses of maintenance therapy showed better DFS (P = 0.0555). The VCR group had significantly worse EFS. By multivariate analysis, significant prognostic factors for the achievement of CR were age less than 60, PS 0-2 and no addition of VCR. Significant factors for longer DFS were induction of CR by one course, FAB M3 or M5 and age less than 50. The present multi-institutional study confirmed the high CR rates of the response-oriented individualized therapy reported from several centers in Japan, but failed to support an additional effect of VCR reported from one center.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1578954

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia.

Authors:  K Ishiga; T Kawatani; T Suou; F Tajima; H Omura; Y Idobe; H Kawasaki
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.

Authors:  Atsushi Wakita; Shigeki Ohtake; Satoru Takada; Fumiharu Yagasaki; Hirokazu Komatsu; Yasushi Miyazaki; Kohmei Kubo; Yukihiko Kimura; Akihiro Takeshita; Yoko Adachi; Hitoshi Kiyoi; Takuhiro Yamaguchi; Minoru Yoshida; Kazunori Ohnishi; Shuichi Miyawaki; Tomoki Naoe; Ryuzo Ueda; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2012-05-26       Impact factor: 2.490

3.  Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.

Authors:  Akihiro Takeshita; Kaori Shinjo; Kensuke Naito; Hirotaka Matsui; Naohi Sahara; Kazuyuki Shigeno; Taeko Suzumura; Toshinobu Horii; Naohito Shirai; Masato Maekawa; Yoshihiro Yada; Hirofumi Teshima; Jin Takeuchi; Kazunori Ohnishi; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

4.  Modulation of the effect of 1-beta-D-arabinofuranosylcytosine by 6-mercaptopurine in L1210 cells.

Authors:  Y Kawai; T Ueda; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1994-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.